Syndax Pharmaceuticals (SNDX) Common Equity (2015 - 2026)

Syndax Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $41.6 million for Q1 2026.

• In Q1 2026, Common Equity fell 80.65% year-over-year to $41.6 million; the TTM figure through Mar 2026 stood at $41.6 million (down 80.65% YoY), while the FY2025 annual figure was $64.6 million, down 77.57% from the prior year.
• Common Equity for Q1 2026 stood at $41.6 million, down from $64.6 million in the prior quarter.
• The five-year high for Common Equity was $554.2 million in Q4 2023, with the low at $41.6 million in Q1 2026.
• The 5-year median for Common Equity is $361.9 million (2022), against an average of $321.5 million.
• The sharpest annual moves came in 2022 and 2026: Common Equity soared 69.9% in 2022, then sank 80.65% in 2026.
• Syndax Pharmaceuticals' Common Equity stood at $467.4 million in 2022, then climbed by 18.56% to $554.2 million in 2023, then plunged by 48.01% to $288.1 million in 2024, then sank by 77.57% to $64.6 million in 2025, then plunged by 35.6% to $41.6 million in 2026.
• Business Quant data shows SNDX's Common Equity at $41.6 million in Q1 2026, $64.6 million in Q4 2025, and $115.4 million in Q3 2025.